- Volume 16 Issue 16
DOI QR Code
Association between the CYP1A2 rs762551 Polymorphism and Bladder Cancer Susceptibility: a Meta-Analysis Based on Case-Control Studies
- Zeng, Yong (Department of Cardiothoracic Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
- Jiang, Hua-Yong (Department of Radiation Oncology, Beijing Military General Hospital) ;
- Wei, Li (Department of Oncology, the 401 hospital of PLA) ;
- Xu, Wei-Dong (Department of Radiation Oncology, Beijing Military General Hospital) ;
- Wang, Ya-Jie (Department of Oncology, Changhai Hospital, Second Military Medical University) ;
- Wang, Ya-Di (Department of Radiation Oncology, Beijing Military General Hospital) ;
- Liu, Chuan (Department of Oncology, Changhai Hospital, Second Military Medical University)
- 발행 : 2015.11.04
Background: Previous studies evaluated associations between the CYP1A2 rs762551 polymorphism and bladder cancer risk. However, the results were inconsistent. We therefore performed a meta-analysis of the published case-control studies to assess in detail the association between CYP1A2 rs762551 polymorphism and bladder cancer risk. Materials and Methods: PubMed, Embase and Web of Science were searched to identify relevant studies and the pooled odds ratio (OR) and 95 % confidence interval (95%CI) were calculated. Results: A total of seven articles including 3,013 cases and 2,771 controls were finally included. Overall, a significant association was found between the CYP1A2 rs762551 polymorphism and bladder cancer susceptibility for CC vs AA (OR=0.82, 95% CI=0.69~0.99), but no significant associations were found for the other three models (AC vs AA: OR=0.91, 95% CI=0.81~1.02; the dominant model: OR=0.90, 95% CI=0.80~1.00; the recessive model: OR=0.84, 95% CI =0.72~1.00). In the subgroup analysis by ethnicity, we detected significant associations between the CYP1A2 rs762551 polymorphism and bladder cancer susceptibility for GA vs GG (OR = 0.78, 95% CI =0.64~0.96) and for the recessive model (OR=0.80, 95% CI=0.66~0.96) in Caucasians, but not for Asians. Conclusions: The results from the meta-analysis suggested that the CYP1A2 rs762551 polymorphism is a protective factor for bladder cancer, especially in Caucasians.
- Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66. https://doi.org/10.1007/s11255-008-9444-6
- Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
- Bozina N, Bradamante V, Lovric M (2009). Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol, 60, 217-42
- Butler MA, Lang NP, Young JF, et al (1992). Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2, 116-27. https://doi.org/10.1097/00008571-199206000-00003
- Chung WG, Kang JH, Park CS, Cho MH, Cha YN (2000). Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther, 67, 258-66. https://doi.org/10.1067/mcp.2000.104617
- Caporaso N, Landi MT, Vineis P (1991). Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1, 4-19 https://doi.org/10.1097/00008571-199110000-00003
- Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
- Cui X, Lu X, Hiura M, et al (2013). Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med, 18, 136-42. https://doi.org/10.1007/s12199-012-0302-x
- DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88 https://doi.org/10.1016/0197-2456(86)90046-2
- Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
- Figueroa JD, Malats N, Garcia-Closas M, et al (2008). Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 29, 1955-62. https://doi.org/10.1093/carcin/bgn163
- Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
- Ioannidis JP, Boffetta P, Little J, et al (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol, 37, 120-32. https://doi.org/10.1093/ije/dym159
- Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X (2009). Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol, 19, 540-6. https://doi.org/10.1097/MOU.0b013e32832eb336
- Kiltie AE (2010). Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev, 20, 218-24. https://doi.org/10.1016/j.gde.2010.01.002
- Li D, Jiao L, Li Y, et al (2006). Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 27, 103-11.
- Mandal RK, Dubey S, Panda AK, Mittal RD (2014). Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis. Tumour Biol, 35, 6415-23 https://doi.org/10.1007/s13277-014-1869-1
- Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48
- Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol, 37, 136-46. https://doi.org/10.1093/ije/dym234
- Miranda CL, Yang YH, Henderson MC, et al (2000). Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cDNAexpressed human CYP1A2. Drug Metab Dispos, 28, 1297-302.
- Nordmark A, Lundgren S, Cnattingius S, Rane A (1999). Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol, 47, 397-402.
- Pavanello S, Simioli P, Lupi S, Gregorio P, Clonfero E (2002). Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomarkers Prev, 11, 998-1003.
- Pavanello S, Mastrangelo G, Placidi D, et al (2010). CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer. Eur J Epidemiol, 25, 491-500. https://doi.org/10.1007/s10654-010-9479-8
- Qiu LX, Yao L, Mao C, Yu KD, Zhan P, et al (2010). Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: A meta-analysis involving 17,600 subjects. Breast Cancer Res Treat, 122, 521-5. https://doi.org/10.1007/s10549-009-0731-4
- Rodriguez-Antona C, Ingelman-Sundberg M (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene, 25, 1679-91. https://doi.org/10.1038/sj.onc.1209377
- Sachse C, Bhambra U, Smith G, et al (2003). Colorectal Cancer Study Group. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol, 55, 68-76. https://doi.org/10.1046/j.1365-2125.2003.01733.x
- Sachse C, Brockmoller J, Bauer S, Roots I (1999). Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47, 445-9.
- Sangrajrang S, Sato Y, Sakamoto H, et al (2009). Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer, 125, 837-43. https://doi.org/10.1002/ijc.24434
- Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988). A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the odeethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol, 26, 363-72. https://doi.org/10.1111/j.1365-2125.1988.tb03393.x
- Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
- Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmeta-analyses. Eur J Epidemiol, 25, 603-5. https://doi.org/10.1007/s10654-010-9491-z
- Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR (2000). Empirical assessment of effect of publication bias on metaanalysis. BMJ, 320, 1574-7. https://doi.org/10.1136/bmj.320.7249.1574
- Tsukino H, Kuroda Y, Nakao H, et al (2004). Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol, 130, 99-106. https://doi.org/10.1007/s00432-003-0512-0
- Villanueva CM, Silverman DT, Murta-Nascimento C, et al (2009). Coffee consumption, genetic susceptibility and bladder cancer risk. Cancer Causes Control, 20, 121-7. https://doi.org/10.1007/s10552-008-9226-6
- Volanis D, Kadiyska T, Galanis A, et al (2010). Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett, 193, 131-7. https://doi.org/10.1016/j.toxlet.2009.12.018
- Wang Y, Kong CZ, Zhang Z, Yang CM, Li J (2014). Relationships between CYP1A1 genetic polymorphisms and bladder cancer risk: a meta-analysis. DNA Cell Biol, 33, 171-81. https://doi.org/10.1089/dna.2013.2298
- Xiong T, Yang J, Wang H, et al (2014). The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer. Mol Biol Rep, 41, 2629-34. https://doi.org/10.1007/s11033-014-3121-x